Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia

Treatment of congenital haemophilia with factor VIII and IX concentrates often requires frequent infusions. This has obvious implications in establishing effective administration strategies and, in turn, adherence. To overcome these issues, three main technologies – polyethylene‐glycol, Fc‐neonatal IgG1 and albumin fusion products – have emerged into various stages of clinical development. Published data indicates an approximately 1·5‐ and fivefold increase in half‐life of factor VIII and IX, respectively, compared to standard recombinant concentrates. Studies into efficacy and safety are starting to be published. Monitoring and optimal use of these new concentrates remains unknown. Weekly factor IX prophylaxis appears to be a feasible prophylactic regimen in haemophilia B patients. Weekly longer‐acting FVIII is unlikely to provide adequate prophylaxis in most patients with haemophilia A but may reduce the frequency of infusions. Ongoing clinical trials and real life experience will help shape how these products can be used in practice and their cost effectiveness. The drive for convenience however should not overshadow the ultimate goal of prophylaxis, namely, preventing bleeding and arthropathy.

[1]  M. Ozelo,et al.  Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates , 2015, British journal of haematology.

[2]  L. Valentino,et al.  The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[4]  E. Santagostino,et al.  Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients , 2014 .

[5]  J. Mahlangu,et al.  Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG) , 2014 .

[6]  E. Santagostino,et al.  Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP) , 2014 .

[7]  L. Boggio,et al.  Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study , 2014 .

[8]  J. Oldenburg,et al.  Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial , 2014 .

[9]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[10]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[11]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[12]  A. Shapiro.  Long-lasting recombinant factor VIII proteins for hemophilia A. , 2013, Hematology. American Society of Hematology. Education Program.

[13]  L. Valentino,et al.  Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein , 2013 .

[14]  E. Santagostino,et al.  Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B , 2013 .

[15]  G. Pierce,et al.  The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein , 2013 .

[16]  S. Björkman.  Population pharmacokinetics of recombinant factor IX: implications for dose tailoring , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[18]  L. Thim,et al.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. , 2013, Blood.

[19]  A. Bitonti,et al.  Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein , 2013, Journal of thrombosis and haemostasis : JTH.

[20]  T. Nichols,et al.  Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8‐GP in haemophilia A dogs , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  G. Di Minno,et al.  Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients , 2012, Thrombosis and Haemostasis.

[22]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[23]  T. Nichols,et al.  Improved kinetics of rIX‐FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs , 2012, Journal of thrombosis and haemostasis : JTH.

[24]  A. Bitonti,et al.  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. , 2012, Blood.

[25]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[26]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[27]  A. Bitonti,et al.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. , 2012, Blood.

[28]  H. Ehrlich,et al.  BAX 855, a PEGylated rFVIII product with prolonged half-life , 2011, Hämostaseologie.

[29]  H. Ehrlich,et al.  Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life , 2011 .

[30]  P. Giangrande,et al.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. , 2011, Blood.

[31]  T. Nichols,et al.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. , 2011, Blood.

[32]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[34]  John E. Murphy,et al.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. , 2010, Blood.

[35]  G. Spotts,et al.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring , 2010, Journal of thrombosis and haemostasis : JTH.

[36]  A. Bitonti,et al.  Prolonged activity of factor IX as a monomeric Fc fusion protein. , 2010, Blood.

[37]  T. Weimer,et al.  Genetic fusion to albumin improves the pharmacokinetic properties of factor IX , 2009, Thrombosis and Haemostasis.

[38]  P. Lenting,et al.  Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients , 2009, PloS one.

[39]  S. Jönsson,et al.  Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.

[40]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[41]  Ji-Yun Kim,et al.  Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. , 2007, Blood.

[42]  H. Stass,et al.  Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. , 2008, Journal of thrombosis and haemostasis : JTH.

[43]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[44]  P. Lenting,et al.  Clearance mechanisms of von Willebrand factor and factor VIII , 2007, Journal of thrombosis and haemostasis : JTH.

[45]  W. Lencer,et al.  A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. , 2005, Trends in cell biology.